SIREN : 497632471
PHARMES is a French company founded 19 years ago, specialized in the sector Conseil pour les affaires et autres conseils de gestion. Based in PARIS (75017), this company of category PME shows in 2022 a revenue of 984 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 984 023 € | 873 772 € | 943 656 € | 892 742 € | 893 234 € | 920 507 € | 1 060 765 € |
| Net income | 38 213 € | 1 410 € | 2 522 € | 3 000 € | -392 € | 19 388 € | 21 780 € |
| EBITDA | 50 524 € | -8 928 € | -12 040 € | 4 223 € | 2 498 € | 23 270 € | 28 005 € |
| Net margin | 3.9% | 0.2% | 0.3% | 0.3% | -0.0% | 2.1% | 2.1% |
In 2022, PHARMES achieves revenue of 984 k€. Activity remains stable over the period (CAGR: -1.2%). Vs 2021, growth of +13% (874 k€ -> 984 k€). After deducting consumption (10 €), gross margin stands at 984 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 51 k€, representing 5.1% of revenue. Positive scissor effect: EBITDA margin improves by +6.2 pts, sign of improved operational efficiency. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 38 k€, i.e. 3.9% of revenue. This profit can be retained or distributed to shareholders.
984 023 €
984 013 €
50 524 €
44 990 €
38 213 €
5.1%
The debt ratio (= Financial debt / Equity x 100) stands at 65%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 25%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.6 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 4.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
64.582%
25.431%
4.537%
1.583
19.5%
In 2022, the debt ratio of PHARMES (64.58) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2022, the financial autonomy of PHARMES (25.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2022, the repayment capacity of PHARMES (1.58) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 171.84. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 1.0x. Danger: operating income does not cover interest charges, unsustainable situation.
171.843
0.996
In 2022, the liquidity ratio of PHARMES (171.84) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2022, the interest coverage of PHARMES (1.0x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 52 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 52 days. WCR is negative (-11 days): operations structurally generate cash. Over 2016-2022, WCR increased by +64%, requiring additional financing.
-30 908 €
52 j
52 j
0 j
-11 j
Based on 88 transactions of similar company sales
in 2022,
the value of PHARMES is estimated at
330 656 €
(range 169 583€ - 687 284€).
With an EBITDA of 50 524€, the sector multiple of 6.8x is applied.
The price/revenue ratio is 0.33x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 88 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARMES with other companies in the same sector:
Voir toutes les statistiques du secteur Conseil pour les affaires et autres conseils de gestion
The revenue of PHARMES in 2022 is 984 k€.
Yes, PHARMES generated a net profit of 38 k€ in 2022.
The headquarters of PHARMES is located in PARIS (75017), in the department Paris.
The tax return of PHARMES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARMES operates in the sector Conseil pour les affaires et autres conseils de gestion (NAF code 70.22Z). See the 'Sector positioning' section above to compare the company with its competitors.